JNCCN 360 - BiomarkerNTRK - Ongoing CE Activities

Editors:

Alexander Drilon, MD

Gregory J. Riely, MD, PhD

Ongoing CE Activities

Emerging and Evolving Biomarkers: NTRK

Expanding Targetable Treatment in Thyroid Cancer: NTRK Fusions

How I Manage Patients With NTRK Fusion–Positive Head and Neck Cancer

NTRK Fusion in Lung Cancer and the Role of TRK Inhibitors

Real World Oncology Rounds: Current Concepts and Recent Advances in Oncology

The Latest Advancements in NTRK: Expert Insights from September 2020

Treatment Advances in NTRK Gene–Fusion Positive Sarcoma: What Do You Need to Know?

Sections

NCCN Resources

360 HUB
About
Contact
Disclaimer
Disclosures
Privacy Policy
Terms Of Use

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.

Ongoing CE Activities

Emerging and Evolving Biomarkers: NTRK

Expanding Targetable Treatment in Thyroid Cancer: <em>NTRK</em> Fusions

How I Manage Patients With <em>NTRK</em> Fusion–Positive Head and Neck Cancer

<em>NTRK</em> Fusion in Lung Cancer and the Role of TRK Inhibitors

Real World Oncology Rounds: Current Concepts and Recent Advances in Oncology

The Latest Advancements in NTRK: Expert Insights from September 2020

Treatment Advances in <em>NTRK</em> Gene–Fusion Positive Sarcoma: What Do You Need to Know?